French Pharma Buys Brain Cancer Drug Maker for $2.5B

French pharmaceutical company Servier is spending $2.5 billion to acquire Day One Biopharmaceuticals, bringing hope to families fighting pediatric brain cancer around the world.

The Bay Area biotech company makes Ojemda, a drug approved in 2024 to treat pediatric low-grade glioma. This is the most common type of brain cancer in children.

Servier agreed to pay $21.50 per share in cash, a 68% premium over Day One's stock price. The privately held French company announced the deal on Friday.

Pediatric low-grade glioma affects thousands of children every year. Before Ojemda's approval, treatment options were limited and often came with harsh side effects that could impact a child's development.

The drug represents years of research focused specifically on how cancer works differently in children's bodies compared to adults. Day One built its entire mission around creating medicines designed for kids, not just adapting adult treatments.

The Ripple Effect

This acquisition means Servier can now use its global distribution network to bring Ojemda to more countries. Families in Europe and beyond will gain access to this specialized treatment faster than a smaller biotech could manage alone.

Servier also gains Day One's pipeline of experimental medicines for other rare cancers. The company said this deal fits perfectly with its strategy of developing treatments for diseases that affect smaller patient populations.

For researchers working on pediatric cancers, the deal sends an encouraging signal. Big pharmaceutical companies are willing to invest billions in medicines for childhood diseases, even though these represent smaller markets than adult treatments.

The transaction shows that focusing on unmet medical needs, especially in children's health, can attract major investment. Other biotech companies working on rare pediatric diseases now have proof that their work has real commercial value.

Parents whose children face brain cancer diagnoses will have more confidence that this treatment will remain available and supported long term. A larger company with deep resources backing Ojemda means continued research, manufacturing, and access programs.

This deal proves that doing good and doing well in business can go hand in hand.